Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jul 8;106(7):dju128.
doi: 10.1093/jnci/dju128. Print 2014 Jul.

Recommended patient-reported core set of symptoms and quality-of-life domains to measure in ovarian cancer treatment trials

Kristine A Donovan  1 , Heidi S Donovan  1 , David Cella  1 , Martha E Gaines  1 , Richard T Penson  1 , Steven C Plaxe  1 , Vivian E von Gruenigen  1 , Deborah Watkins Bruner  1 , Bryce B Reeve  1 , Lari Wenzel  2
Affiliations
Review

Recommended patient-reported core set of symptoms and quality-of-life domains to measure in ovarian cancer treatment trials

Kristine A Donovan et al. J Natl Cancer Inst. .

Abstract

There is no consensus as to what symptoms or quality-of-life (QOL) domains should be measured as patient-reported outcomes (PROs) in ovarian cancer clinical trials. A panel of experts convened by the National Cancer Institute reviewed studies published between January 2000 and August 2011. The results were included in and combined with an expert consensus-building process to identify the most salient PROs for ovarian cancer clinical trials. We identified a set of PROs specific to ovarian cancer: abdominal pain, bloating, cramping, fear of recurrence/disease progression, indigestion, sexual dysfunction, vomiting, weight gain, and weight loss. Additional PROs identified in parallel with a group charged with identifying the most important PROs across cancer types were anorexia, cognitive problems, constipation, diarrhea, dyspnea, fatigue, nausea, neuropathy, pain, and insomnia. Physical and emotional domains were considered to be the most salient domains of QOL. Findings of the review and consensus process provide good support for use of these ovarian cancer-specific PROs in ovarian cancer clinical trials.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Study identification.
See this image and copyright information in PMC

Comment in

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29 - PubMed
    1. Bookman MA. Standard treatment in advanced ovarian cancer in 2005: the state of the art. Int J Gynecol Cancer. 2005;15(Suppl 3):212–220 - PubMed
    1. Ozols RF. Maintenance therapy in advanced ovarian cancer: progression-free survival and clinical benefit. J Clin Oncol. 2003;21(13):2451–2453 - PubMed
    1. Cleeland CS, Sloan JA, Group AO. Assessing the Symptoms of Cancer Using Patient-Reported Outcomes (ASCPRO): searching for standards. J Pain Symptom Manage. 2010; 39 (6):1077–1085 - PubMed
    1. US Department of Health & Human Services Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. 2009. http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf - PubMed

Publication types

MeSH terms

Substances